NOVATARG, INC.
Biotech · Acquired
Novel biguanide small molecule (NT1195) for type 2 diabetes treatment in patients with kidney disease
- Grants
- $5.5M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 5
- 3 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Novel and Kidney Selective AMPK Activators to Treat Polycystic Kidney Disease | $474,273 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Biguanides to Treat Type 2 Diabetes | $1,639,823 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel and Kidney Selective AMPK Activators to Treat Polycystic Kidney Disease | $1,109,281 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Biguanides to Treat Type 2 Diabetes | $987,938 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Biguanides to Treat Type 2 Diabetes | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Biguanides to Treat Type 2 Diabetes | $284,611 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2136 | Richard Fisher | — | — |
| 2137 | PLEXYMER, INC. | — | — |
| 2138 | SGN, Inc. | — | $3.8M |
| 2139 | NOVATARG, INC. | — | — |
| 2140 | Helix Alternative Technologies Inc. | — | $6.0M |
| 2141 | ImmunoMolecular Therapeutics, Inc. | — | $11M |
| 2142 | CELLECHO INC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Fused Bicyclic Alkylene Linked Imidodicarbonimidic Diamides, Methods For Synthesis, And Uses In Therapyapplication
- Fused Bicyclic Alkylene Linked Imidodicarbonimidic Diamides, Methods For Synthesis, And Uses In Therapygranted
- Fused Bicyclic Alkylene Linked Imidodicarbonimidic Diamides, Methods For Synthesis, And Uses In Therapygranted
- Fused Bicyclic Alkylene Linked Imidodicarbonimidic Diamides, Methods For Synthesis, And Uses In Therapygranted
- Fused Bicyclic Alkylene Linked Imidodicarbonimidic Diamides, Methods For Synthesis, And Uses In Theraryapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.